Literature DB >> 9604865

Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice.

R Tisch1, R S Liblau, X D Yang, P Liblau, H O McDevitt.   

Abstract

IDDM is a T-cell-mediated autoimmune disease in which the insulin-producing beta-cells are destroyed. The disease process is complex, involving the recognition of several beta-cell autoantigens. One of these, GAD65, appears to have a critical and not fully defined role in IDDM in humans and in the NOD mouse. We provide evidence that an ongoing diabetogenic response in NOD mice can be suppressed after intravenous administration of GAD65, but not by other beta-cell autoantigens. Furthermore, suppression of the diabetogenic response is mediated by the induction of GAD65-specific CD4+ regulatory T-cells. Finally, cytokine analysis indicates that these CD4+ regulatory T-cells have a T-helper 2 phenotype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9604865     DOI: 10.2337/diabetes.47.6.894

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  43 in total

1.  DNA vaccination encoding glutamic acid decarboxylase can enhance insulitis and diabetes in correlation with a specific Th2/3 CD4 T cell response in non-obese diabetic mice.

Authors:  A Gauvrit; M Debailleul; A-T Vu; P Sai; J-M Bach
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 2.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

Review 3.  T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Authors:  Jeffrey Babad; Ari Geliebter; Teresa P DiLorenzo
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

4.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 6.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 7.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

8.  Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 17.152

9.  IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease.

Authors:  Eva d'Hennezel; Mara Kornete; Ciriaco A Piccirillo
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

10.  Glutamic acid decarboxylase-derived epitopes with specific domains expand CD4(+)CD25(+) regulatory T cells.

Authors:  Guojiang Chen; Gencheng Han; Jiannan Feng; Jianan Wang; Renxi Wang; Ruonan Xu; Beifen Shen; Jiahua Qian; Yan Li
Journal:  PLoS One       Date:  2009-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.